financetom
Business
financetom
/
Business
/
Why Capri Holdings And Tapestry Shares Are Falling Today
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Capri Holdings And Tapestry Shares Are Falling Today
Apr 23, 2024 10:42 AM

Capri Holdings Limited ( CPRI ) shares are trading lower on Tuesday, together with Tapestry, Inc. ( TPR ) . 

The Federal Trade Commission filed a lawsuit aiming to halt Tapestry’s $8.5 billion purchase of Capri Holdings ( CPRI ). 

The acquisition seeks to combine three close competitors – Tapestry’s Coach and Kate Spade brands and Capri’s Michael Kors brand, per the FTC.

“With the goal to become a serial acquirer, Tapestry seeks to acquire Capri to further entrench its stronghold in the fashion industry,” said Henry Liu, Director of the FTC’s Bureau of Competition. “This deal threatens to deprive consumers of the competition for affordable handbags, while hourly workers stand to lose the benefits of higher wages and more favorable workplace conditions.”

FTC said the merger proposal jeopardizes the advantages of Tapestry and Capri’s direct competition for millions of American consumers. These benefits encompass price rivalry, discounts, innovation, design, marketing, and advertising.

“The market realities, which the government’s challenge ignores, overwhelmingly demonstrate that this transaction will not limit, reduce, or constrain competition,” Capri Holdings ( CPRI ) said in a press release. 

The U.S. FTC is the only regulator that did not approve this transaction, which received required approvals from all other jurisdictions, the company added. 

In bringing this case, the FTC has chosen to ignore the reality of today’s dynamic and expanding $200 billion global luxury industry, Tapestry said in a press release.

“We have strong legal arguments in defense of this transaction and look forward to presenting them in court and working expeditiously to close the transaction in calendar year 2024,” Tapestry added.

Price Action: TPR shares are trading lower by 0.67% to $40.04 at the last check Tuesday, while CPRI shares are trading lower by 3.13% to $36.79.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Marsh Mclennan Agency Acquires Robins Insurance
BRIEF-Marsh Mclennan Agency Acquires Robins Insurance
Sep 2, 2025
Marsh & McLennan Companies Inc ( MMC ): * MARSH MCLENNAN AGENCY ACQUIRES ROBINS INSURANCE * MARSH & MCLENNAN ( MMC ): TERMS OF ACQUISITION WERE NOT DISCLOSED Source text: Further company coverage: ...
PepsiCo Investor Elliott Demands Revamp of Beverage, Food Businesses
PepsiCo Investor Elliott Demands Revamp of Beverage, Food Businesses
Sep 2, 2025
11:04 AM EDT, 09/02/2025 (MT Newswires) -- PepsiCo's ( PEP ) shares rose on Tuesday as Elliott Investment Management urged the company to revamp its North American beverages and snacks businesses in a move that the activist investor said would unlock additional shareholder value. Elliot, which holds a $4 billion stake in Pepsi, said that the owner of brands including...
Darden Restaurants' Setup Into Fiscal 1Q Earnings Positive, Says Truist Securities
Darden Restaurants' Setup Into Fiscal 1Q Earnings Positive, Says Truist Securities
Sep 2, 2025
11:01 AM EDT, 09/02/2025 (MT Newswires) -- Darden Restaurants' ( DRI ) setup into fiscal Q1 earnings is positive, with a solid beat expected and a potentially raised fiscal 2026 guidance expected, Truist Securities said in a Tuesday note ahead of Darden Restaurants' ( DRI ) Q1 results due Sept. 18. Truist Securities increased its fiscal Q1 same-store sales and...
Eupraxia Reports Positive 12-Month Results From RESOLVE Trial
Eupraxia Reports Positive 12-Month Results From RESOLVE Trial
Sep 2, 2025
11:02 AM EDT, 09/02/2025 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) , up 1% on last look, on Tuesday announced additional positive clinical data from its Phase 1b/2a RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (EoE). It noted patients treated with 4mg per injection of EP-104GI had meaningful levels of clinical remission at Week 12, right...
Copyright 2023-2026 - www.financetom.com All Rights Reserved